Company profile
HLS Therapeutics Inc.
OTC: HLTRF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Etobicoke, ONReports USD
#416 of 1,418 Healthcare companies by revenue40th-percentile growth
EA Score
64CFH 67DQ —GM 56SS 63
v0.1 · 45/100 weight · provisional
↑ growth stability, Piotroski F · ↓ 3-yr revenue growth, revenue growth (YoY)
Methodology →Revenue TTM
$55.8M
Rev growth YoY (TTM)
-1.7%
Net income (FY)
-$12.6M
Employees
85
as of 2026-08-18
Market cap
$85.4M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$56.5M$56.5M2025
Net income-$12.6M-$12.6M2025
Operating income-$4.2M-$4.2M2025
Total assets$137.3M$137.3M2025
Liabilities$75.7M$75.7M2025
Equity$61.6M$61.6M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is HLS Therapeutics Inc.’s revenue?
HLS Therapeutics Inc. booked $56.5M in FY2025 revenue, contracting 0.3% year over year — about the middle of the pack among Healthcare companies we track, at a -22.4% net margin.
Peers · Healthcare
Flower One Holdings Inc.——Champions Oncology, Inc.——CVRx, Inc.50D908 Devices Inc.60CNektar Therapeutics50DThe Joint Corp.75B+Key facts
CEOCraig Stuart Millian
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersEtobicoke, ON
ExchangeOTC: HLTRF
Employees85
IPO date2010-01-27
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.